Arrowhead Pharmaceuticals (0HI3) Share Forecast & Price Target
0HI3 Analyst Ratings
Strong Buy
12Buy1Hold0Sell
Based on 13 analysts giving stock ratings to Arrowhead Pharmaceuticals in the past 3 months
0HI3 Stock 12 Month Forecast
Average Price Target
$109.00▲(84.81% Upside)Based on 13 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $109.00 with a high forecast of $126.00 and a low forecast of $74.00. The average price target represents a 84.81% change from the last price of $58.98.
Past 12 Months12 Month ForecastDec2025Sep2026
High$126.00
Average$109.00
Low$74.00
Highest Price TargetHighest$126.00Average Price Target$109.00Lowest Price TargetLowest$74.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | UBS | $109 | buy | 84.81%Upside | Initiated | 10/20/26 | ||
| Patrick Trucchio | H.C. Wainwright | $120 | buy | 103.46%Upside | Reiterated | 10/15/26 | ||
| Edward Tenthoff | Piper Sandler | $126 | buy | 113.63%Upside | Reiterated | 10/15/26 | ||
| Brian Cheng | J.P. Morgan | ― | buy | ― | Reiterated | 10/15/26 | ||
| Eric Joseph | Citi | $108 | buy | 83.11%Upside | Reiterated | 10/14/26 | ||
| Jason Gerberry | Bank of America Securities | $100 | buy | 69.55%Upside | Reiterated | 10/12/26 | ||
| Andrea Newkirk | Goldman Sachs | $74 | hold | 25.47%Upside | Initiated | 09/24/26 | ||
| James Condulis | Stifel Nicolaus | $104 | buy | 76.33%Upside | Reiterated | 08/31/26 | ||
| Michael Ulz | Morgan Stanley | $120 | buy | 103.46%Upside | Reiterated | 08/31/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 08/30/26 | ||
| Luca Issi | RBC Capital | $100 | buy | 69.55%Upside | Reiterated | 08/30/26 | ||
| Madison Elsaadi | B. Riley Securities | $123 | buy | 108.55%Upside | Reiterated | 08/05/26 | ||
| Keay Nakae | Chardan Capital | $115 | buy | 94.98%Upside | Reiterated | 08/04/26 | ||
| William Pickering | Bernstein | $35→$46 | hold | -22.01%Downside | Assigned | 05/13/26 | ||
| Mani Foroohar | Leerink Partners | ― | hold | ― | Reiterated | 03/26/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Unknown AnalystNot Ranked | 10/20/26 | $109 | buy | 84.81%Upside | Initiated | UBS | ||
| Patrick Trucchio | 10/15/26 | $120 | buy | 103.46%Upside | Reiterated | H.C. Wainwright | ||
| Edward Tenthoff | 10/15/26 | $126 | buy | 113.63%Upside | Reiterated | Piper Sandler | ||
| Brian Cheng | 10/15/26 | ― | buy | ― | Reiterated | J.P. Morgan | ||
| Eric Joseph | 10/14/26 | $108 | buy | 83.11%Upside | Reiterated | Citi | ||
| Jason Gerberry | 10/12/26 | $100 | buy | 69.55%Upside | Reiterated | Bank of America Securities | ||
| Andrea Newkirk | 09/24/26 | $74 | hold | 25.47%Upside | Initiated | Goldman Sachs | ||
| James Condulis | 08/31/26 | $104 | buy | 76.33%Upside | Reiterated | Stifel Nicolaus | ||
| Michael Ulz | 08/31/26 | $120 | buy | 103.46%Upside | Reiterated | Morgan Stanley | ||
| Joseph Thome | 08/30/26 | ― | buy | ― | Reiterated | TD Cowen | ||
| Luca Issi | 08/30/26 | $100 | buy | 69.55%Upside | Reiterated | RBC Capital | ||
| Madison Elsaadi | 08/05/26 | $123 | buy | 108.55%Upside | Reiterated | B. Riley Securities | ||
| Keay Nakae | 08/04/26 | $115 | buy | 94.98%Upside | Reiterated | Chardan Capital | ||
| William Pickering | 05/13/26 | $35→$46 | hold | -22.01%Downside | Assigned | Bernstein | ||
| Mani Foroohar | 03/26/26 | ― | hold | ― | Reiterated | Leerink Partners |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Arrowhead Pharmaceuticals
3 Months
Success Rate16/25 ratings generated profit
64%
Average Return
+27.01%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 64.00% of your transactions generating a profit, with an average return of +27.01% per trade.
1 Year
Success Rate15/25 ratings generated profit
60%
Average Return
+117.57%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +117.57% per trade.
2 Years
Success Rate14/21 ratings generated profit
67%
Average Return
+102.36%
Copying Jason Gerberry's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +102.36% per trade.
0HI3 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 0 | 1 | 7 |
| Buy | 19 | 30 | 35 | 33 | 20 |
| Hold | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 22 | 32 | 35 | 35 | 28 |
In the current month, 0HI3 has received 27 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0HI3 average Analyst price target in the past 3 months is 109.00.
0HI3 Financial Forecast
High$-0.35
Consensus$-1.52
Low$-3.00
0HI3 Earnings Forecast
Next quarter’s earnings estimate for 0HI3 is -$1.52 with a range of -$3.00 to -$0.35. The previous quarter’s EPS was -$1.36. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$178M
Consensus$61.2M
Low$4.5M
0HI3 Sales Forecast
Next quarter’s sales forecast for 0HI3 is $61.18M with a range of $4.50M to $178.00M. The previous quarter’s sales results were $75.25M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0HI3 Stock Forecast FAQ
What is GB:0HI3’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is $109.00.
What is GB:0HI3’s upside potential, based on the analysts’ average price target?
Arrowhead Pharmaceuticals has 84.81% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Arrowhead Pharmaceuticals a Buy, Sell or Hold?
Arrowhead Pharmaceuticals has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
What is Arrowhead Pharmaceuticals’s share price target?
The average share price target for Arrowhead Pharmaceuticals is $109.00. This is based on 13 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $126.00, and the lowest forecast is $74.00. The average share price target represents a 84.81% increase from the current price of $58.98.
What do analysts say about Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Street analysts.
How can I buy shares of Arrowhead Pharmaceuticals?
To buy shares of GB:0HI3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.